SEC Comment Letter 0000000000-23-014043 to Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc.
Date: Dec. 22, 2023 · CIK: 0001796280 · Accession: 0000000000-23-014043
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276077
Letter
United States securities and exchange commission logo December 22, 2023 Dominic Piscitelli Chief Financial Officer Oric Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080 Re:Oric Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed December 15, 2023 File No. 333-276077 Dear Dominic Piscitelli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Amanda Urquiza
Show Raw Text
United States securities and exchange commission logo
December 22, 2023
Dominic Piscitelli
Chief Financial Officer
Oric Pharmaceuticals, Inc.
240 E. Grand Ave, 2nd Floor
South San Francisco, CA 94080
Re:Oric Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed December 15, 2023
File No. 333-276077
Dear Dominic Piscitelli:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Amanda Urquiza